Icatibant Fresenius (Icatibant Acetate)

Icatibant is a targeted therapy for bradykinin‑mediated angioedema conditions, providing rapid symptom relief.

• Acute hereditary angioedema attacks: reduces swelling and shortens the duration of an episode.
• Hereditary angioedema type I: controls episodic edema during attacks.
• Hereditary angioedema type II: alleviates swelling when attacks occur.

• Icatibant selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑induced vasodilation and increased vascular permeability. By inhibiting this pathway, the drug curtails the cascade that leads to fluid extravasation and tissue swelling characteristic of hereditary angioedema attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects

• Injection site pain: discomfort at the site of administration.
• Redness or erythema: localized skin irritation.
• Swelling at injection site: mild edema around the needle area.
• Nausea: occasional gastrointestinal upset.
• Headache: transient cranial discomfort.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Hypersensitivity reactions: rash, itching, or hives.
• Anaphylaxis: severe, potentially life‑threatening allergic response.
• Severe hypotension: marked drop in blood pressure requiring medical attention.

Before using Icatibant, clinicians should consider several safety measures to minimize risks.

• Assess patient for known hypersensitivity: avoid use if a prior allergic reaction to icatibant or its excipients has occurred.
• Monitor airway after injection: observe for signs of airway obstruction, especially in severe attacks.
• Use with caution in renal impairment: adjust monitoring as drug clearance may be affected.
• Pregnancy and lactation: safety data are limited; weigh potential benefits against unknown risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence bradykinin levels or vascular tone.

Major Interactions (Avoid)

• ACE inhibitors: may increase bradykinin concentrations and raise the risk of angioedema.
• Concomitant use of other bradykinin B2 antagonists: additive pharmacologic effect could lead to unexpected outcomes.

Moderate Interactions (Monitor Closely)

• NSAIDs: may exacerbate swelling or interfere with symptom control.
• Estrogen‑containing contraceptives: can increase frequency of hereditary angioedema attacks.
• C1‑inhibitor concentrate therapy: no direct interaction, but clinical monitoring is advised when both are used sequentially.